Hengeler Mueller advises Minapharm on acquisition of majority stake in ProBioGen

21. June 2010

Minapharm Pharmaceuticals S.A.E., Cairo (www.minapharm.com), one of the leading pharmaceutical companies for prescription medication in Egypt and the Middle East, which specialises in the manufacture and marketing of innovative specialty pharmaceuticals and in the development and manufacture of biopharmaceutical medication as well as being listed on the Egyptian stock exchange, has acquired a 95% shareholding in Berlin-based ProBioGen AG, a company specialised in mammalian cell engineering and cell culture. The purchase price amounts to approximately EUR 30 m. This transaction is one of the few involving investments of Egyptian companies in Germany and the first of its kind in the field of biotechnology.

Hengeler Mueller has advised Minapharm Pharmaceuticals on this transaction. The Hengeler Mueller team was led by partners Cord-Georg Hasselmann and Nicolas Böhm (both M&A/Corporate, Berlin) and included partner Hans-Joachim Liebers (Labour, Frankfurt) and associates Stefan Schäfers, Robert Thamm (both M&A/Corporate, Berlin), Christian Schröder (IP) and Susanne Koch (Regulatory) (both Düsseldorf) as well as David Schneider (Labour, Frankfurt).